Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets

Ebolaviruses are highly lethal filoviruses that cause hemorrhagic fever in humans and nonhuman primates. With no approved treatments or preventatives, the development of an anti‐ebolavirus therapy to protect against natural infections and potential weaponization is an urgent global health need. Here, we describe the design, biophysical characterization, and validation of peptide mimics of the ebolavirus N‐trimer, a highly conserved region of the GP2 fusion protein, to be used as targets to develop broad‐spectrum inhibitors of ebolavirus entry. The N‐trimer region of GP2 is 90% identical across all ebolavirus species and forms a critical part of the prehairpin intermediate that is exposed during viral entry. Specifically, we fused designed coiled coils to the N‐trimer to present it as a soluble trimeric coiled coil as it appears during membrane fusion. Circular dichroism, sedimentation equilibrium, and X‐ray crystallography analyses reveal the helical, trimeric structure of the designed N‐trimer mimic targets. Surface plasmon resonance studies validate that the N‐trimer mimic binds its native ligand, the C‐peptide region of GP2. The longest N‐trimer mimic also inhibits virus entry, thereby confirming binding of the C‐peptide region during viral entry and the presence of a vulnerable prehairpin intermediate. Using phage display as a model system, we validate the suitability of the N‐trimer mimics as drug screening targets. Finally, we describe the foundational work to use the N‐trimer mimics as targets in mirror‐image phage display, which will be used to identify D‐peptide inhibitors of ebolavirus entry.

[1]  B. Autran,et al.  Bioterrorism: management of major biological agents. , 2006, Cellular and molecular life sciences : CMLS.

[2]  Matthew T. Weinstock,et al.  Protease‐resistant peptide design—empowering nature's fragile warriors against HIV , 2012, Biopolymers.

[3]  H. Feldmann,et al.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. , 2011, Journal of bioterrorism & biodefense.

[4]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[5]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[6]  P. S. Kim,et al.  Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[8]  I. Brooks,et al.  Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. , 1993, Analytical biochemistry.

[9]  H. Feldmann,et al.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Weissenhorn,et al.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. , 1998, Molecular cell.

[11]  C. Wohlfarth Partial specific volume of poly(ethylene glycol) , 2010 .

[12]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[13]  Brian G Fox,et al.  A combined approach to improving large-scale production of tobacco etch virus protease. , 2007, Protein expression and purification.

[14]  S. Whelan,et al.  Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection , 2005, Science.

[15]  R. Ray,et al.  Identification of a Small-Molecule Entry Inhibitor for Filoviruses , 2011, Journal of Virology.

[16]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[17]  J. Kuhn,et al.  Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor* , 2006, Journal of Biological Chemistry.

[18]  S. Danishefsky,et al.  Free-radical-based, specific desulfurization of cysteine: a powerful advance in the synthesis of polypeptides and glycopolypeptides. , 2007, Angewandte Chemie.

[19]  Kathryn L. Schornberg,et al.  A new player in the puzzle of filovirus entry , 2012, Nature Reviews Microbiology.

[20]  P. Dawson,et al.  An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. , 2008, Angewandte Chemie.

[21]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[22]  Lorenz M. Mayr,et al.  Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.

[23]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[24]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[25]  J. Condra,et al.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 , 2009, mAbs.

[26]  D. Eckert,et al.  Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. , 2012, Bioconjugate chemistry.

[27]  E. Saphire,et al.  Ebolavirus glycoprotein structure and mechanism of entry. , 2009, Future virology.

[28]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[29]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[30]  R. Andino,et al.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.

[31]  J. Berg,et al.  A comparison of the immunogenicity of a pair of enantiomeric proteins , 1993, Proteins.

[32]  J. Berg,et al.  A racemic protein , 1992 .

[33]  K. Chandran,et al.  Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes , 2011, The Journal of Biological Chemistry.

[34]  M. Root,et al.  HIV-1 gp41 as a target for viral entry inhibition. , 2004, Current pharmaceutical design.

[35]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[36]  K. A. Noren,et al.  Construction of high-complexity combinatorial phage display peptide libraries. , 2001, Methods.

[37]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[39]  P. Iversen,et al.  Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.

[40]  A. Sanchez,et al.  The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Tompa Polymer solutions , 1956 .

[42]  Ming-Tsair Wey,et al.  Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors , 2008, Antiviral Research.

[43]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[44]  R. L. Baldwin,et al.  Comparison of NH exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. , 1997, Biochemistry.

[45]  K. Chandran,et al.  Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: Stability and pH effects , 2011, Protein science : a publication of the Protein Society.

[46]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.

[47]  Gennaro Ciliberto,et al.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. S. Kim,et al.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[50]  Helena Berglund,et al.  Improved solubility of TEV protease by directed evolution. , 2006, Journal of biotechnology.

[51]  Kathryn L. Schornberg,et al.  Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein , 2006, Journal of Virology.

[52]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[53]  Brett D. Welch,et al.  Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.

[54]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[55]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[56]  Kathryn L. Schornberg,et al.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. , 2008, Critical reviews in biochemistry and molecular biology.

[57]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[58]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[59]  C. Hill,et al.  Design of a Potent d-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance , 2010, Journal of Virology.

[60]  William J. Salerno,et al.  MONSTER: inferring non-covalent interactions in macromolecular structures from atomic coordinate data , 2004, Nucleic Acids Res..

[61]  A. Sanchez,et al.  Covalent Modifications of the Ebola Virus Glycoprotein , 2002, Journal of Virology.

[62]  R. Lamb,et al.  A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. , 1998, Virology.

[63]  T J Cieslak,et al.  Biological warfare : A historical perspective , 1997 .

[64]  Majidat A. Muhammad,et al.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.

[65]  H. Feldmann,et al.  Proteolytic processing of Marburg virus glycoprotein. , 2000, Virology.

[66]  D. Schwarzer,et al.  Chemoselective ligation and modification strategies for peptides and proteins. , 2008, Angewandte Chemie.

[67]  D. Littman,et al.  Packaging system for rapid production of murine leukemia virus vectors with variable tropism , 1992, Journal of virology.

[68]  Matthew T. Weinstock,et al.  Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity , 2014, Proceedings of the National Academy of Sciences.

[69]  James L Cole,et al.  Analysis of heterogeneous interactions. , 2004, Methods in enzymology.

[70]  Shinji Watanabe,et al.  Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein , 2000, Journal of Virology.

[71]  P. S. Kim,et al.  Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. , 1998, Journal of molecular biology.

[72]  Claire Marie Filone,et al.  Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences , 2012, Journal of Virology.

[73]  K. Chandran,et al.  C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking. , 2013, Bioorganic & medicinal chemistry letters.